Addressing Health Literacy With a Tailored Survivorship Care Plan

Summary

This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.

Conditions

• Localized Prostate Carcinoma
• Oligometastatic Prostate Carcinoma
• Stage IVB Prostate Cancer AJCC v8

Interventions

OTHER

Educational Intervention

Receive a low literacy educational supplement

OTHER

Interview

Undergo a structured interview

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Supportive Care

Receive standard SCP

OTHER

Supportive Care

Receive a tailored SCP

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• United States Department of Defense

  collaborator FED

• Emory University

  lead OTHER

Principal Investigators

• Viraj Master, MD, PhD, FACS · Emory University Hospital/Winship Cancer Institute

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-11-07

Primary Completion

2029-12-31

Completion

2030-12-31

Countries

• United States

Study Locations